# ALA-101

Source: https://onco.cc/drugs/ala-101/  
OnCo record `ala-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ALA-101 is an experimental allogeneic CAR-iNKT cell therapy from Arovella Therapeutics, in phase 1 trials for CD19-positive B-cell lymphoma, CD19-positive leukaemia and non-Hodgkin lymphoma.

## Summary

ALA-101 (CAR19-iNKT) is an allogeneic CAR-iNKT cell therapy from Arovella Therapeutics. Off-the-shelf invariant natural killer T (iNKT) cells carrying a chimeric antigen receptor against CD19; the company says lymphomas that also express CD1d bound to a glycolipid can be recognised by the iNKT cells' own receptor, making them dual targeting. Its furthest stage is phase 1, for CD19-positive B-cell lymphoma, CD19-positive leukaemia and non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07518329 recruiting; registry start date 19 October 2026. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: CAR19-iNKT
- Tags: pipeline; ctgov-ingest
- Code: ALA-101
- Modality: Allogeneic CAR-iNKT cell therapy
- Mechanism: Off-the-shelf invariant natural killer T (iNKT) cells carrying a chimeric antigen receptor against CD19; the company says lymphomas that also express CD1d bound to a glycolipid can be recognised by the iNKT cells' own receptor, making them dual targeting.

## Sources

- Arovella Therapeutics: arovella.com: https://www.arovella.com/ala-101-car19-inkt
- Arovella Therapeutics: arovella.com: https://www.arovella.com/ala-101-car19-inkt
- Arovella Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07518329
- ClinicalTrials.gov: trials of ALA-101: https://clinicaltrials.gov/search?intr=ALA-101

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [Arovella Therapeutics](https://onco.cc/companies/arovella-therapeutics/)
- trials: [Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.](https://onco.cc/trials/nct07518329/)

---
JSON: https://onco.cc/api/v1/entities/ala-101.json